John M. Pagel, MD, PhD
Chief of Hematologic Malignancies and Director of Stem Cell Transplantation
Swedish Cancer Institute
Hear Dr. John Pagel present current treatment approaches for patients with newly diagnosed relapsed chronic lymphocytic leukemia (CLL) with an emphasis on the latest data from the 2018 ASH Annual Meeting. This presentation focuses on the diminishing role of chemoimmunotherapy for this disease type, the expanding relevance of B-cell receptors and Bcl-2 inhibitors, and ongoing combination studies in the treatment-naïve and relapsed/refractory CLL settings.